Noteable Neurology Advancements of 2018

References:

1. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018 Sep 1;75(9):1080-1088. doi: 10.1001/jamaneurol.2018.1212.2. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018 Jul;38(8):1442-1454. doi: 10.1177/0333102418779543.3. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018 Nov 16. pii: 10.1212/WNL.0000000000006640. doi: 10.1212/WNL.0000000000006640.4. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.5. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.6. Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017 Nov 30;377(22):2123-2132. doi: 10.1056/NEJMoa1705848.7. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0.8. Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 May;38(6):1026-1037. doi: 10.1177/0333102418759786. Epub 2018 Feb 22.9. Alzheimer’s Association International Conference. BAN2401 Phase 2 Data released at AAIC 2018. July 22-26, 2018, Chicago, ILL. https://www.alz.org/aaic/releases_2018/AAIC18-Wed-3-30-pm.asp. Accessed December 12, 2018.10. Eisai. Eisai and biogen announce detailed results of phase II clinical study of BAN2401 in early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018. https://www.eisai.com/news/2018/news201866.html. Accessed December 12, 2018.11. Swanson CJ, Zhang Y, Dhadda S, et al. Treatment of Early AD subjects with BAN2401, an Anti-Aβ Protofibril Monoclonal Antibody, Significantly Clears Amyloid Plaque and Reduces Clinical Decline. Abstract 27531. https://ep70.eventpilotadmin.com/web/page.php?page=IntHtml&project=AAIC18&id=27531. Accessed December 12, 2018.12. Portola pharmaceuticals. U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors. https://globenewswire.com/news-release/2018/05/04/1496534/0/en/U-S-FDA-Approves-Portola-Pharmaceuticals-Andexxa-First-and-Only-Antidote-for-the-Reversal-of-Factor-Xa-Inhibitors.html. Accessed December 12, 2018.13. Boehringer Ingelheim. FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa. https://www.boehringer-ingelheim.us/press-release/fda-provides-full-approval-praxbind-specific-reversal-agent-pradaxa. Accessed December 12, 2018.14. Montalban X, Arnold DL, Weber MS, et al. Abstract 322: Primary analysis of a randomised, placebo-controlled, phase 2 study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis. Presented at the European Committee for treatment and research in multiple sclerosis. October 10-12, Berlin, Germany.15. Howsmon DP, Kruger U, Melnyk S, et al. Classification and adaptive behavior prediction of children with autism spectrum disorder based upon multivariate data analysis of markers of oxidative stress and DNA methylation. PLoS Comput Biol. 2017 Mar 16;13(3):e1005385. doi: 10.1371/journal.pcbi.1005385.16. Howsmon DP, Vargason T, Rubin RA, et al. Multivariate techniques enable a biochemical classification of children with autism spectrum disorder versus typically-developing peers: A comparison and validation study. Bioeng Transl Med. 2018 Jun 19;3(2):156-165. doi: 10.1002/btm2.10095.17. Anwar A, Abruzzo PM, Pasha S, et al. Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism - a source of biomarkers for clinical diagnosis. Mol Autism. 2018 Feb 19;9:3. doi: 10.1186/s13229-017-0183-3.